RCUS$24.25
$23.78
Chart
Performance
Key Stats
AI RCUS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyArcus Biosciences shows promising thematic alignment in the oncology space and positive performance trends, but faces financial challenges and mixed technical signals. Investors should consider the high-risk, high-reward nature of this clinical-stage biopharma.
Thematic
Arcus Biosciences is strategically positioned in the high-growth oncology market, with a focus on novel immuno-oncology targets like TIGIT and CD73, which are key areas of innovation in cancer treatment.
Fundamental
While revenue and profit are currently negative, indicative of a clinical-stage biopharma, the company's balance sheet shows a notable increase in cash, crucial for funding its extensive clinical development. However, valuation metrics are difficult to interpret in the absence of profitability.
Technical
The stock has experienced recent price appreciation over shorter timeframes (1M, 5D), indicating positive momentum, but is trading below its 52-week high and exhibits mixed signals across various technical indicators.
| Factor | Score |
|---|---|
| Oncology Drug Development | 95 |
| Biopharma Innovation | 90 |
| Targeted Therapies | 80 |
| Market Trends (IO) | 85 |
| Regulatory Landscape | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Price Action | 75 |
| Volatility | 60 |
| Trading Volume | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Attractive Valuation
The current Price-to-Sales (PS) ratio is 10.1, which is lower than the previous year's 11.2 and the trailing twelve months (TTM) PS ratio of 10.1 suggests potential undervaluation relative to revenue.
Positive Short-Term Performance
The stock has shown positive performance over the last 1 month (+14.29%) and 5 days (+4.91%), indicating recent positive investor sentiment.
Bearish Points (8)
Consistent Net Losses
The company has reported net losses for the past several years (2022-2024), with net income figures consistently negative and significant in magnitude, indicating a lack of profitability.
High Price-to-Sales Ratio
The current Price-to-Sales (PS) ratio of 10.1 is high, especially considering the company's lack of profitability, suggesting a premium valuation that may not be justified by current earnings.
Calendar
August 2025
7
Next Earnings Date
H: $-1.10
A: $-1.17
L: $-1.21
H: 65.00M
A: 32.86M
L: 20.00M
Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Seasonals
Price Target
28.18 USD
The 39 analysts offering 1 year price forecasts for RCUS have a max estimate of 46.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Major strategic collaboration partner with Arcus Biosciences across multiple immuno-oncology programs, including TIGIT and adenosine pathway.
Weight: 95
Direct competitor in TIGIT (tiragolumab program) and a leading global pharmaceutical company with a significant immuno-oncology pipeline.
Weight: 90
Developer of Keytruda (PD-1 inhibitor), a foundational drug in immuno-oncology often used in combination therapies, and actively exploring new IO pathways.
Weight: 88
Major player in immuno-oncology with Opdivo (PD-1) and Yervoy (CTLA-4), extensive oncology pipeline.